

13 August 2025

ASX Announcement

Nasodine COVID-19 Patent Accepted in Europe

- Patent covers use of Nasodine to reduce shedding of SARS-CoV-2
- Patent now accepted or granted in US, Europe, Australia, Mexico, South Africa

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that it has received acceptance of its COVID-19 patent by the European Patent Office ("EPO"). This patent is already granted in US, Mexico, Australia and South Africa, and applications in other countries are pending.

The patent will now proceed to a national validation process under which up to 38 participating countries in Europe (specific countries to be selected by Firebrick) will also grant the patent.

The patent protects the use of Nasodine[®] Nasal Spray ("Nasodine") and any other intranasal povidone-iodine (PVP-I) preparations as a method of reducing the viral load of SARS-CoV-2 in the nose. Granted claims also cover pre-exposure prophylaxis (preventative use prior to exposure) against SARS-CoV-2, notably in the case of healthcare workers.

This patent is supported by the published clinical trial (announcements 7 August 2023 and 2 April 2024), which showed that in COVID-19 subjects with early symptoms, the frequent use of Nasodine over three days resulted in 100% clearance of the virus from the nasal passages.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine[®] Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with a launch in the Philippines expected in 2026.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com